文献速递乳腺癌支持与姑息治疗

乳腺癌诊断后严重疲乏预测模型的开发与验证:迈向个体化生存期照护框架

Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.
PubMed 文献 · J Clin Oncol · 2022-01-21

研究基于CANTO前瞻性队列,纳入I-III期乳腺癌患者,在诊断时及诊断后1、2、4年收集数据,开发并验证预测诊断后2年严重整体疲乏的模型。模型纳入治疗前严重疲乏、年轻年龄、较高体质指数、当前吸烟、较差的焦虑、失眠和诊断时疼痛,受试者工作特征曲线下面积为0.73(95%CI 0.72-0.75)。作者提出该模型可帮助临床医生早期干预或纠正可改变的危险因素。

要点

  • 治疗前严重疲乏是治疗后2年严重整体疲乏的最强预测因子(调整OR 3.191)。
  • 模型纳入年轻年龄、较高体质指数、当前吸烟、焦虑、失眠和疼痛,AUC为0.73。
  • 接受激素治疗与诊断后4年严重疲乏相关(调整OR 1.448)。

核心结论

  • 作者提出一个用于评估乳腺癌生存者疲乏的预测模型,置于个体化生存期照护框架内,可能帮助临床医生提供早期管理干预或纠正可改变的危险因素,并为有严重治疗后疲乏风险的患者提供更量身定制的监测和教育。

研究设计与样本

  • 前瞻性纳入CANTO研究(ClinicalTrials.gov标识符NCT01993498)中I-III期乳腺癌患者,在诊断时(任何癌症治疗开始前)及诊断后1年(T1)、2年(T2)、4年(T3)收集纵向数据。
  • 主要结局为T2时严重整体疲乏(欧洲癌症研究与治疗组织生活质量问卷-C30评分≥40/100),T3时分析为探索性。
  • 采用多变量逻辑回归模型,通过自举增强后退消除法保留与严重疲乏的关联。
  • 验证方法包括10折内部交叉验证、过度乐观校正的受试者工作特征曲线下面积和外部验证。

主要发现

  • 在T1、T2和T3分别有5,640、5,000和3,400例患者,开发队列中治疗后严重整体疲乏的患病率分别为35.6%、34.0%和31.5%。
  • T2时严重整体疲乏的保留危险因素包括:治疗前严重疲乏(对比无,调整OR 3.191 [95%CI 2.704-3.767])、年轻年龄(每减少1岁,OR 1.015 [95%CI 1.009-1.022])、较高体质指数(每增加1个单位,OR 1.025 [95%CI 1.012-1.038])、当前吸烟行为(对比从不吸烟,OR 1.552 [95%CI 1.291-1.866])、较差的焦虑(对比非病例,OR 1.265 [95%CI 1.073-1.492])、失眠(每增加1个单位,OR 1.005 [95%CI 1.003-1.007])和诊断时疼痛(每增加1个单位,OR 1.014 [95%CI 1.010-1.017]),受试者工作特征曲线下面积为0.73(95%CI 0.72-0.75)。
  • 接受激素治疗是T3时严重疲乏的危险因素(对比无,OR 1.448 [95%CI 1.165-1.799])。
  • 维度特异性危险因素包括体质指数与躯体疲乏相关,情绪困扰与情绪和认知疲乏相关。

临床怎么用

  • 作者提出该预测模型可用于个体化生存期照护框架内评估乳腺癌生存者的疲乏,可能帮助临床医生提供早期管理干预或纠正可改变的危险因素,并为有严重治疗后疲乏风险的患者提供更量身定制的监测和教育。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fatigue is common and troublesome among breast cancer survivors; however, limited tools exist to predict its risk. PATIENTS AND METHODS: Participants with stage I-III breast cancer were prospectively included from CANTO (ClinicalTrials.gov identifier: NCT01993498), collecting longitudinal data at diagnosis (before the initiation of any cancer treatment) and 1 (T1), 2 (T2), and 4 (T3) years after diagnosis. The main outcome was severe global fatigue at T2 (score ≥ 40/100, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30). Analyses at T3 were exploratory. Secondary outcomes included physical, emotional, and cognitive fatigue (EORTC Quality of Life Questionnaire-FA12). Multivariable logistic regression models retained associations with severe fatigue by bootstrapped Augmented Backward Elimination. Validation methods included 10-fold internal cross-validation, overoptimism-corrected area under the receiver operating characteristic curves, and external validation. RESULTS: Among 5,640, 5,000, and 3,400 patients at T1, T2, and T3, respectively, the prevalence of post-treatment severe global fatigue was 35.6%, 34.0%, and 31.5% in the development cohort. Retained risk factors for severe global fatigue at T2 were severe pretreatment fatigue (adjusted odds ratio v no 3.191 [95% CI, 2.704 to 3.767]); younger age (for 1-year decrement 1.015 [1.009 to 1.022]), higher body mass index (for unit increment 1.025 [1.012 to 1.038]), current smoking behavior (v never 1.552 [1.291 to 1.866]), worse anxiety (v noncase 1.265 [1.073 to 1.492]), insomnia (for unit increment 1.005 [1.003 to 1.007]), and pain at diagnosis (for unit increment 1.014 [1.010 to 1.017]), with an area under the receiver operating characteristic curve of 0.73 (95% CI, 0.72 to 0.75). Receipt of hormonal therapy was a risk factor for severe fatigue at T3 (v no 1.448 [1.165 to 1.799]). Dimension-specific risk factors included body mass index for physical fatigue and emotional distress for emotional and cognitive fatigue. CONCLUSION: We propose a predictive model to assess fatigue among breast cancer survivors, within a personalized survivorship care framework. This may help clinicians to provide early management interventions or to correct modifiable risk factors and offer more tailored monitoring and education to patients at risk of severe post-treatment fatigue.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Di Meglio A, Havas J, Soldato D, et al. Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. J Clin Oncol. 2022. PMID: 35061509. doi:10.1200/JCO.21.01252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。